SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Claritev Corporation (NYSE: CTEV). The investigation focuses on Claritev’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Claritev securities? If you purchased Claritev securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact ...

PresentationI will now hand the conference over to Todd Friedman, Head of Investor Relations. Todd, please go ahead.Ladies and gentlemen, thank you for joining us, and welcome to the Claritev Corporation Fourth Quarter 2025 Earnings Call. [Operator Instructions].Todd FriedmanVice President of Investor Relations Thank you, operator. Good afternoon and welcome to Claritev's fourth quarter 2025 earnings call. Joining me today are Travis Dalton, President and Chief Executive Officer; and Doug Garis, Chief Finan ...

分组1 - Claritev Corporation reported a quarterly loss of $4.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.96, representing an earnings surprise of -23.23% [1] - The company posted revenues of $246.55 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.13%, and showing an increase from $232.15 million year-over-year [2] - Claritev Corporation has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.75 on revenues of $243.21 million, and for the current fiscal year, it is -$14.26 on revenues of $992.62 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - KORU Medical Systems, Inc. (KRMD) experienced a significant stock price increase of 5.6% due to positive investor sentiment following FDA clearance for its FreedomEDGE infusion system, which enhances the delivery of large-volume subcutaneous drugs [1][2]. Financial Performance - The company is projected to report a quarterly loss of $0.02 per share, reflecting a year-over-year improvement of 33.3%. Expected revenues are $10.89 million, representing a 23.2% increase from the same quarter last year [3]. - The consensus EPS estimate for KORU Medical Systems has remained stable over the past 30 days, indicating no recent revisions in earnings estimates, which typically correlate with stock price movements [4]. Industry Context - KORU Medical Systems is part of the Zacks Medical Info Systems industry, where Claritev Corporation (CTEV) also operates. CTEV's stock closed 2.3% higher but has seen a decline of 19.9% over the past month [4].

Company Overview - Claritev, formerly known as MultiPlan, is undergoing a transformation under the leadership of CEO Travis Dalton, who joined in March 2024 [1] - The company focuses on providing clear insights around pricing and aims to assist employers in managing risk and employee benefits [2] Industry Insights - The healthcare industry is currently emphasizing transparency, which is seen as a key focus for the company moving forward [2] - Claritev has been dedicated to affordability solutions in healthcare for nearly 40 years, showcasing its long-standing commitment to the sector [2]

Core Viewpoint - Claritev Corporation is focused on making healthcare more affordable, transparent, and fair for all, and will present at the 44th Annual J.P. Morgan Healthcare Conference [1] Company Participation - Claritev Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference [1] - The management presentation is scheduled for Thursday, January 15, 2026, at 7:30 a.m. PT [1] - A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's website [1]

Claritev Corporation (NYSE:CTEV) FY Conference December 04, 2025 08:00 AM ET Company ParticipantsDoug Garis - CFOTravis Dalton - President and CEOConference Call ParticipantsJess Tassin - AnalystJess TassinHi, everyone. Thanks so much for joining. My name's Jess Tassin. I cover managed care and healthcare IT at Piper. I'm really excited to be here with Claritev Management this morning. We've got CEO Travis Dalton and CFO Doug Garis on stage with me. Travis and Doug, thank you guys so much for being here.Tra ...

PresentationLarry BlandBofA Securities, Research Division Thank you, everyone. Thanks for -- I guess, first and foremost, thanks for everyone for joining us at the conference. Really appreciate it. And we especially want to thank, I've said, the management team starting with the team from Claritev Corporation. Doug Garis, Chief Financial Officer is with us. Doug, a lot of great things to talk about. I thought maybe we'd just start by general introduction. Obviously, it's been a good year, a big turn. So, I ...

Claritev Corporation (NYSE:CTEV) 2025 Conference Summary Company Overview - **Company**: Claritev Corporation - **Industry**: Healthcare Technology and Services - **Conference Date**: December 02, 2025 Key Points Company Performance and Strategy - 2024 was a foundational year for Claritev, while 2025 marked a significant turnaround, focusing on sustainable growth [3][4] - The company has identified its core business as a growth business, managing five internal P&Ls and opening six new market segments [4][5] New Market Segments - Claritev has expanded into six new market segments, including: 1. **Provider Market**: Introduction of a transparency product called CompleteView for pricing transparency [9] 2. **International Market**: Advanced Code Editing product aimed at denial management for providers, particularly in the Middle East [10][11] 3. **Government Segment**: Selling core products to federal agencies, with a notable win expected to be announced in Q4 [11] 4. **Employer Space**: BenInsights platform for self-insured employers to manage healthcare costs [12] Financial Metrics - The company expects to book at least $60 million in Annual Contract Value (ACV) for 2025, with 491 deals closed year-to-date averaging $80,000-$90,000 [24][26] - The pipeline is approximately $200 million, with 55% from the current install base [26] International Expansion - Claritev is leveraging previous relationships to explore international markets, particularly focusing on denial management solutions [15][16] - The company aims to address inefficiencies in healthcare systems in about three dozen countries that have adopted U.S. coding standards [16] Competitive Advantage - Claritev's Advanced Code Editing has shown significant results, reducing denial rates for Burjeel Holdings from 7% to 3.5%, translating to $40 million in economic value [18][19] - The company is positioned uniquely in the market, focusing on direct-to-provider solutions rather than traditional methods of managing denials [19] Technology and Partnerships - A strategic partnership with Oracle has enabled rapid deployment of technology solutions, enhancing operational efficiency [34][35] - The relationship with Oracle is evolving into a go-to-market strategy, with Oracle Cloud representatives now selling Claritev's solutions [35] Operational Improvements - The company has focused on improving its financial operations and accountability, leading to a more efficient structure with 3% less headcount while growing the business [43][44] - Emphasis on mastering the basics, including the use of Salesforce for pipeline management, has been crucial for stabilization [45][46] Future Outlook - Claritev views its entire business as a growth opportunity, with significant potential in the network business and government sector [51][52] - The company is optimistic about its ability to accelerate investments in international markets as it gains proof of value [17][46] Additional Insights - The healthcare industry is facing significant challenges, with denial rates being a critical issue for providers [20][21] - Claritev's solutions are designed to optimize cash flow for providers, addressing both payer and provider needs [22][21] - The company is committed to making healthcare more transparent and affordable, which is reflected in its strategic partnerships and product offerings [48][49]

Core Viewpoint - Claritev Corporation has announced the pricing of a public offering of 1,500,000 shares of its Class A common stock, aiming to enhance its position in the healthcare technology sector [1] Group 1: Company Overview - Claritev Corporation is a technology, data, and insights company focused on making healthcare more affordable, transparent, and fair for all [1] Group 2: Offering Details - The public offering consists of 1,500,000 shares of Class A common stock with a par value of $0.0001 per share [1] - The shares are being offered by certain affiliates of Hellman & Friedman, referred to as the Selling Stockholders [1]